The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Gusev E.I.

Pirogov National Research Medical University

Blokhin V.E.

Koltsov Institute of Developmental Biology RAS

Vartanov S.A.

Moscow School of Economics of the Lomonosov Moscow State University

Martynov M.U.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnology of the Federal Medical Biological Agency

Katunina E.A.

Federal Center of Brain and Neurotechnologies;
Pirogov Russian National Research Medical University

Alessenko A.V.

Institute of Biochemical Physic of the Russian Academy of Sciences

Denisova I.A.

Moscow School of Economics of the Lomonosov Moscow State University

Pavlova E.N.

Koltsov Institute of Developmental Biology RAS

Polterovich V.M.

Moscow School of Economics of the Lomonosov Moscow State University;
Central Economic and Mathematical Institute of the Russian Academy of Sciences

Kucheryanu V.G.

Institute of General Pathology and Pathophysiology

Shupik M.A.

Institute of Biochemical Physic of the Russian Academy of Sciences

Nodel M.R.

Sechenov First Moscow State Medical University

Kalinkin A.L.

Medical Research and Education Center of Lomonosov Moscow State University

Sokolov S.A.

Lomonosov Moscow State University

Chubarova T.V.

Institute of Economics of the Russian Academy of Sciences

Shakleina M.V.

Moscow School of Economics of the Lomonosov Moscow State University

Pronina T.S.

Koltsov Institute of Developmental Biology of the Russian Academy of Sciences

Ugrumov M.V.

Koltsov Institute of Developmental Biology RAS

Development of early diagnosis of Parkinson’s disease and comprehensive economic analysis of the effect of its implementation

Authors:

Gusev E.I., Blokhin V.E., Vartanov S.A., Martynov M.U., Katunina E.A., Alessenko A.V., Denisova I.A., Pavlova E.N., Polterovich V.M., Kucheryanu V.G., Shupik M.A., Nodel M.R., Kalinkin A.L., Sokolov S.A., Chubarova T.V., Shakleina M.V., Pronina T.S., Ugrumov M.V.

More about the authors

Read: 3585 times


To cite this article:

Gusev EI, Blokhin VE, Vartanov SA, et al. . Development of early diagnosis of Parkinson’s disease and comprehensive economic analysis of the effect of its implementation. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(1):9‑20. (In Russ.)
https://doi.org/10.17116/jnevro20211210119

Recommended articles:
Sarcopenia as a non-motor symptom of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):15-22
Asso­ciation of inflammation and chro­nic fati­gue syndrome in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):79-87
Diagnosis and treatment approaches for sialorrhea in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):29-34
Neurochemical mechanisms of tremor in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):64-72
Cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):81-90
Bladder dysfunction in patients with stages I—III of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):91-99

References:

  1. Weerkamp NJ, Zuidema SU, Tissingh G, et al. Motor profile and drug treatment of nursing home residents with Parkinson’s disease. J Am Geriatr Soc. 2012;60(12):2277–2282. https://doi.org/10.1111/jgs.12027
  2. Schrag A, Hommel ALAJ, Lorenzl S, et al. The late stage of Parkinson’s -results of a large multinational study on motor and non-motor complications. Parkinsonism Relat Disord. 2020;75:91–96.  https://doi.org/10.1016/j.parkreldis.2020.05.016
  3. Steece-Collier K, Maries E, Kordower JH. Etiology of Parkinson’s disease: Genetics and environment revisited. Proc Natl Acad Sci USA. 2002;99(22):13972–13974. https://doi.org/10.1073/pnas.242594999
  4. Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson; disease in the most populous nations, 2005 through 2030. Neurology. 2007;68(5):384–386.  https://doi.org/10.1212/01.wnl.0000247740.47667.03
  5. Rodríguez-Blázquez C, Forjaz MJ, Lizán L, et al. Estimating the direct and indirect costs associated with Parkinson’s disease. Expert Rev Pharmacoecon Outcomes Res. 2015;15(6):889–911.  https://doi.org/10.1586/14737167.2015.1103184
  6. Bovolenta T, de Azevedo Silva S, Arb Saba R, et al. Systematic review and critical analysis of cost studies associated with Parkinson’s disease. Parkinsons Dis. 2017;2017:3410946. https://doi.org/10.1155/2017/3410946.
  7. Marincola FM. Translational Medicine: A two-way road. J Transl Med. 2003;1(1):1.  https://doi.org/10.1186/1479-5876-1-1
  8. Jameson JL, Longo DL. Precision medicine – personalized, problematic, and promising. N Engl J Med. 2015;372(23):2229–-2234. https://doi.org/10.1056/NEJMsb1503104
  9. Gitler AD, Dhillon P, Shorter J. Neurodegenerative disease: models, mechanisms, and a new hope. Dis Model Mech. 2017;10(5):499–502.  https://doi.org/10.1242/dmm.030205
  10. Aaseth J, Dusek P, Roos PM. Prevention of progression in Parkinson’s disease. BioMetals. 2018;31(5):737–747.  https://doi.org/10.1007/s10534-018-0131-5
  11. Ugrumov M. Development of early diagnosis of Parkinson’s disease: illusion or reality? CNS Neurosci Ther. 2020;00:1-13.  https://doi.org/10.1111/cns.13429
  12. Agid Y. Parkinson’s disease: pathophysiology. Lancet. 1991;337(8753):1321–1324. https://doi.org/10.1016/0140-6736(91)92989-f
  13. Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron. 2003;39(6):889–909.  https://doi.org/10.1016/s0896-6273(03)00568-3
  14. Galvan A, Wichmann T. Pathophysiology of Parkinsonism. Clin Neurophysiol. 2008;119(7):1459–1474. https://doi.org/10.1016/j.clinph.2008.03.017
  15. Raza C, Anjum R, Shakeel NUA. Parkinson’s disease: Mechanisms, translational models and management strategies. Life Sci. 2019;226:77–90.  https://doi.org/10.1016/j.lfs.2019.03.057
  16. Jellinger KA. Neuropathobiology of non-motor symptoms in Parkinson disease. J Neural Transm (Vienna). 2015;122(10):1429–1440. https://doi.org/10.1007/s00702-015-1405-5
  17. Maiti P, Manna J, Dunbar GL. Current understanding of the molecular mechanisms in Parkinson’s disease: Targets for potential treatments. Transl Neurodegener. 2017;6:28.  https://doi.org/10.1186/s40035-017-0099-z
  18. Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain. 1991;114(5):2283–2301. https://doi.org/10.1093/brain/114.5.2283
  19. Greffard S, Verny M, Bonnet AM, et al. Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch Neurol. 2006;63(4):584–588.  https://doi.org/10.1001/archneur.63.4.584
  20. Del Tredici K, Braak H. Lewy pathology and neurodegeneration in premotor Parkinson’s disease. Mov Disord. 2012;27(5):597–607.  https://doi.org/10.1002/mds.24921
  21. Berg D, Postuma RB, Adler CH, et al. MDS research criteria for prodromal Parkinson’s disease. Mov Disord. 2015;30(12):1600–1611. https://doi.org/10.1002/mds.26431
  22. Mahlknecht P, Poewe W. Defining premotor Parkinson’s disease: a window of opportunity for neuroprotection? Neurodegenerative Disease Management. 2013;3(1):61–70.  https://doi.org/10.2217/nmt.12.74
  23. Mahlknecht P, Seppi K, Poewe W. The Concept of Prodromal Parkinson’s Disease. J Parkinsons Dis. 2015;5(4):681–697.  https://doi.org/10.3233/JPD-150685
  24. Maiti P, Manna J, Dunbar GL. Current understanding of the molecular mechanisms in Parkinson’s disease: Targets for potential treatments. Transl Neurodegener. 2017;6:28.  https://doi.org/10.1186/s40035-017-0099-z
  25. Antoniades CA, Barker RA. The search for biomarkers in Parkinson’s disease: a critical review. Expert Rev Neurother. 2008;8(12):1841–1852. https://doi.org/10.1586/14737175.8.12.1841
  26. Morrish PK, Rakshi JS, Bailey DL, et al. Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry. 1998;64(3):314–319.  https://doi.org/10.1136/jnnp.64.3.314
  27. Hilker R, Schweitzer K, Coburger S, et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol. 2005;62(3):378–382.  https://doi.org/10.1001/archneur.62.3.378
  28. De la Fuente-Fernández R, Schulzer M, Kuramoto L, et al. Age-specific progression of nigrostriatal dysfunction in Parkinson’s disease. Ann Neurol. 2011;69(5):803–810.  https://doi.org/10.1002/ana.22284
  29. Peng S, Doudet DJ, Dhawan V, Ma Y. Dopamine: PET Imaging and Parkinson Disease. PET Clin. 2013;8(4):469–485.  https://doi.org/10.1016/j.cpet.2013.08.003
  30. Scherzer CR, Eklund AC, Morse LJ, et al. Molecular markers of early Parkinson’s disease based on gene expression in blood. Proc Natl Acad Sci USA. 2007;104(3):955–960.  https://doi.org/10.1073/pnas.0610204104
  31. Mollenhauer B, Zhang J. Biochemical premotor biomarkers for Parkinson’s disease. Mov Disord. 2012;27(5):644–650.  https://doi.org/10.1002/mds.24956
  32. Braak H, Del Tredici K, Bratzke H, et al. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson’s disease (preclinical and clinical stages). J Neurol. 2002;249(Suppl 3):III/1-5.  https://doi.org/10.1007/s00415-002-1301-4
  33. Dickson DW, Fujishiro H, Orr C, et al. Neuropathology of non-motor features of Parkinson disease. Parkinsonism Relat Disord. 2009;15(3):1–5.  https://doi.org/10.1016/S1353-8020(09)70769-2
  34. Hawkes CH. The prodromal phase of sporadic Parkinson’s disease: does it exist and if so how long is it? Mov Disord. 2008;23(13):1799–1807. https://doi.org/10.1002/mds.22242
  35. Gaenslen A, Swid I, Liepelt-Scarfone I, et al. The patients’ perception of prodromal symptoms before the initial diagnosis of Parkinson’s disease. Mov Disord. 2011;26(4):653–658.  https://doi.org/10.1002/mds.23499
  36. Pont-Sunyer C, Hotter A, Gaig C, et al. The onset of nonmotor symptoms in Parkinson’s disease (the ONSET PD study). Mov Disord. 2015;30(2):229–237.  https://doi.org/10.1002/mds.26077
  37. Schrag A, Horsfall L, Walters K, et al. Prediagnostic presentations of Parkinson’s disease in primary care: a case-control study. Lancet Neurol. 2015;14(1):57–64.  https://doi.org/10.1016/S1474-4422(14)70287-X
  38. Jecmenica-Lukic M, Poewe W, Tolosa E, Wenning GK. Premotor signs and symptoms of multiple system atrophy. Lancet Neurol. 2012;11(4):361–368.  https://doi.org/10.1016/S1474-4422(12)70022-4
  39. Donaghy PC, McKeith IG. The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis. Alzheimers Res Ther. 2014;6(4):46.  https://doi.org/10.1186/alzrt274
  40. McKeith IG, Ferman TJ, Thomas AJ, et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology. 2020;94(17):743–755.  https://doi.org/10.1212/WNL.0000000000009323
  41. Yu Z, Stewart T, Aasly J, et al. Combining clinical and biofluid markers for early Parkinson’s disease detection. Ann Clin Transl Neurol. 2017;5(1):109–114.  https://doi.org/10.1002/acn3.509
  42. Li T, Le W. Biomarkers for Parkinson’s Disease: How Good Are They? Neurosci Bull. 2020;36(2):183–194.  https://doi.org/10.1007/s12264-019-00433-1
  43. Kim A, Nigmatullina R, Zalyalova Z, et al. Upgraded methodology for the development of early diagnosis of Parkinson’s Disease based on searching blood markers in patients and experimental models. Mol Neurobiol. 2019;56(5):3437–3450. https://doi.org/10.1007/s12035-018-1315-2
  44. Ugrumov MV, Khaindrava VG, Kozina EA, et al. Modeling of presymptomatic and symptomatic stages of parkinsonism in mice. Neuroscience. 2011;181:175–188. 
  45. Mingazov ER, Khakimova GR, Kozina EA, et al. MPTP Mouse Model of Preclinical and Clinical Parkinson’s Disease as an Instrument for Translational Medicine. Mol Neurobiol. 2018;55(4):2991–3006. https://doi.org/10.1007/s12035-017-0559-6
  46. Swanson CR, Berlyand Y, Xie XS, et al. Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson’s disease patients. Mov Disord. 2015:30:1648–1656. https://doi.org/10.1002/mds.26290
  47. Campolo J, De Maria R, Cozzi L, et al. Antioxidant and inflammatory biomarkers for the identification of prodromal Parkinson’s disease. J Neurol Sci. 2016;370:167–172.  https://doi.org/10.1016/j.jns.2016.09.050
  48. Lahut S, Gispert S, Ömür Ö, et al. Blood RNA biomarkers in prodromal PARK4 and rapid eye movement sleep behavior disorder show role of complexin 1 loss for risk of Parkinson’s disease. Dis Model Mech. 2017;10(5):619–631.  https://doi.org/10.1242/dmm.028035
  49. Tysnes OB, Storstein A. Epidemiology of Parkinson’s disease. J Neural Transm (Vienna). 2017;124(8):901–905.  https://doi.org/10.1007/s00702-017-1686-y
  50. Marino BLB, de Souza LR, Sousa KPA, et al. Parkinson’s Disease: A Review from pathophysiology to treatment. Mini Rev Med Chem. 2020;20(9):754–767.  https://doi.org/10.2174/1389557519666191104110908
  51. Alessenko AV, Albi E. Exploring sphingolipid implications in neurodegeneration. Front Neurol. 2020;11:437.  https://doi.org/10.3389/fneur.2020.00437
  52. Cipriani S, Chen X, Schwarzschild MA. Urate: a novel biomarker of Parkinson’s disease risk, diagnosis and prognosis. Biomark Med. 2010;4(5):701–712.  https://doi.org/10.2217/bmm.10.94.
  53. Wen M, Zhou B, Chen YH, et al. Serum uric acid levels in patients with Parkinson’s disease: A meta-analysis. PLoS One. 2017;12(3):e0173731. https://doi.org/10.1371/journal.pone.0173731
  54. Uribe-San MR, Venegas FP, López IF, et al. Plasma urate in REM sleep behavior disorder. Mov Disord. 2013;28(8):1150–1151. https://doi.org/10.1002/mds.25441
  55. Van Wamelen DJ, Taddei RN, Calvano A, et al. Serum Uric Acid Levels and Non-Motor Symptoms in Parkinson’s Disease. J Parkinsons Dis. 2020;10(3):1003–1010. https://doi.org/10.3233/JPD-201988
  56. Shakleina M, Bogatova I, Vartanov S, et al. Socioeconomic determinants of parkinson’s disease for developed and developing countries. Economics and Mathematical Methods. 2020;56(4):53–66. (In Russ.). https://doi.org/10.31857/S042473880012424-5 
  57. Ball N, Teo WP, Chandra S, Chapman J. Parkinson’s disease and the environment. Frontiers in Neurology. 2019;10:218.  https://doi.org/10.3389/fneur.2019.00218
  58. Lim SY, Tan AH, Ahmad-Annuar A, et al. Parkinson’s disease in the Western Pacific Region. Lancet Neurol. 2019;18(9):865–879.  https://doi.org/10.1016/S1474-4422(19)30195-4
  59. Denisova IA, Chubarova TV, Bogatova IE, et al. Estimating economic efficiency of preclinical diagnostics of Parkinson disease with cost-utility approach. Munich Personal RePEc Archive, posted 22 Oct 2020. Accessed Jan 18, 2021. (In Russ.). https://mpra.ub.uni-muenchen.de/103691
  60. Neumann PJ. Using Cost-Effectiveness Analysis to Improve Healthcare. NY, USA: Oxford University Press; 2005.
  61. Gosse SD. Assessing Cost effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008;8(2):165–178.  https://doi.org/10.1586/14737167.8.2.165
  62. Munoz DA, Kilinc MS, Nembhard HB, et al. Evaluating the Cost-Effectiveness of an Early Detection of Parkinson’s Disease through Innovative Technology. Eng Econ. 2017;62(2):180–196.  https://doi.org/10.1080/0013791X.2017.1294718
  63. Vartanov SA, Bogatova IE, Denisova IA, et al. Cost-effectiveness of preclinical parkinsonism diagnosis: a markov model. Izvestiya Dal’nevostochnogo federal’nogo universiteta. Ekonomika i upravlenie. 2020;(4):129–148. (In Russ.).] https://doi.org/10.24866/2311-2271/2020-4/129-148
  64. Rudakova AV, Levin OS. Pharmacoeconomic aspects of combination therapy for advanced stage of Parkinson’s disease. Nervnye bolezni. 2017;(2):30–34. (In Russ.). https://doi.org/10.17116/jnevro20171176296-100
  65. Lowin J, Sail K, Baj R, et al. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson’s disease. J Med Econ. 2017;20(11):1207–1215. https://doi.org/10.1080/13696998.2017.1379411
  66. Johnson SJ, Diener MD, Kaltenboeck A, et al. An economic model of Parkinson’s disease: Implications for slowing progression in the United States. Mov Disord. 2013;28(3):319–326.  https://doi.org/10.1002/mds.25328.
  67. Siderowf A, Ravina B, Glick HA. Preference-based quality-of-life in patients with Parkinson’s disease. Neurology. 2002;59(1):103–108.  https://doi.org/10.1212/wnl.59.1.103

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.